CDK6


Also found in: Acronyms.

CDK6

A gene on chromosome 7q21-q22 that encodes a cyclin-dependent kinase, which is a catalytic subunit of the protein kinase complex important in cell cycle G1-phase progression and G1/S transition. CDK6, with CDK4, phosphorylates and regulates the activity of tumour suppressor protein Rb.

Molecular pathology
CDK6 expression is upregulated in some cancers.
References in periodicals archive ?
Consistent with the results of the FACS assay, the expression of cyclin D1, CDK4 and CDK6 was down-regulated after 24 h-AB23 treatment (Fig.
Honokiol provoked signal-transducing downregulation of CDK6, CDK4, cyclin Dl, phosphorylated (p)RB, and E2F1.
During early G1 phase, Cyclin D1 binds to and activates CDK4 and CDK6 kinases, which leads to phosphorylation of Retinoblastoma protein, thus contributing to its inactivation.
PQ relies on the use of potent and selective inhibitors of cellular enzymes called CDK4 and CDK6.
La ciclina CD1 se une y activa a CDK4 y CDK6, promoviendo el paso de G1/S.
Antibodies against cyclin D1, phospho-cyclin D1 (Thr286), HA-tag, CDK4, CDK6 and /S-actin were purchased from Cell Signaling (Bervely, MA, USA).
The germline mutation on VHL is a cause of von Hippel-Lindau syndrome); CCND1, cyclin D1 (cyclin D1 controls cell cycle by regulating CDK4 and CDK6 activity which is required for G1/S transition); CDKN2A, cyclin dependent kinase inhibitor 2A (cyclin dependent kinase inhibitor 2A regulates cell cycle G1 progression by inhibiting CDK4 kinase.
The technology has already been successfully utilised to find key cancer mutations, including amplifications in ERBB2 (HER2/neu), MET and CDK6, in cancer patients' blood.
Antibodies against Bach1 (sc-14700), Bcl2 (sc-7382), Bcl-xL (sc-8392), HO-1 (sc-1796), cyclin D1 (sc-20044), cyclin E2 (sc-28351), cyclin B1 (sc-595), CDK2 (sc-163), CDK4 (sc-601), CDK6 (sc-177), p21 (sc-397), p53 (sc-126), the human Bach1 siRNA (sc-37064), and the control siRNA were obtained from Santa Cruz Biotechnology (Santa Cruz, CA).
Cell cycle arrest at sub-G1 phase was induced by rosamultic acid along with downregulation of expression levels of CDK4, CDK6 and cydin D1.
MicroRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma.
Antibodies against PPAR[gamma], C/EBP[alpha], C/EBP(3, GLUT4, pmTOR, p-C/EBP[beta], p-P70S6K, p-P44/42, p-Akt, CDK6 and LRP were purchased from Cell Signaling Technology (Beverly, MA).